No products in the cart.
Live light. Live well.
Fit Light Medtech exists to change this.
Lastest technology procedures
THE CARE YOU NEED
Live light. Live well.
Fit Light Medtech exists to change this.
Live light. Live well.
Fit Light Medtech exists to change this.
Live light. Live well.
Millions cope with conditions that rarely prove fatal , yet quietly erode the quality of every single day. These high-prevalence, refractory diseases are too common to ignore, yet too “benign” to command the scientific attention they deserve.
Fit Light Medtech exists to change this.
Refractory Diseases
Chronic Pharyngitis
Prevalence: 10-30%
Level of Misery:
★★★
Frozen Shoulder
Prevalence: 2-5%
Level of Misery:
★★★★★
ADHD
Prevalence: ~5-7%
Level of Misery:
★★★★
Chronic Insomnia
Prevalence: ~10-15%
Level of Misery:
★★★★
Knee Osteoarthritis
Prevalence: ~16%
Level of Misery:
★★★★★
Hemorrhoidal Disease
Prevalence: ~26%
Level of Misery:
★★★★
Hair Loss
Prevalence: ~2%
Level of Misery:
★★★★
Acne Vulgaris
Prevalence: ~20.5%
Level of Misery:
★★★★
"These conditions are too common to ignore, yet too 'benign' to command the scientific attention they deserve."
— Fit light Medtech Founding Conviction
Fit light Medtech is dedicated to the scientific translation of high-prevalence, refractory conditions — systematically converting overlooked suffering into evidence-based, multimodal therapeutic solutions.
R&D Platform
Two core academic cooperation platforms driving innovation in drug development.
Integrated Development of
Organoid-Chip Systems
Joint development with the State Key Laboratory of Digital Medical Engineering of Southeast University (ranked No.1 in China in intelligent medicine).
- High-efficiency screening and validation in in vitro biomimetic human microphysiological environment
- Development and training of organ-specific AI data capabilities
- AI4GUT drug screening system targeting hemorrhoidal disease
Strategic Scientific &
Technological Cooperation with Leading European Natural Pharmaceutical Chemistry Institutions
In-depth negotiations with top-tier European institutions specializing in natural pharmaceutical chemistry, with decades of pioneering expertise in bioactive natural compound isolation and molecular mechanism validation.
- European expertise: Isolation, structural identification, and molecular mechanism validation
- Synergistic model: "Origin Discovery in Europe + In-depth Development in China"
- Bringing nature's medicine from laboratory to patients worldwide
Product Pipeline
Two major therapeutic areas: the Gastrointestinal system and the Central Nervous System (CNS)
Gastrointestinale system
Natural and Pharmaceutical Chemical Drugs
Co-formulation research
Development Status
33%
Medical Apparatus and Instruments
medical apparatus and instruments
Development Status
50%
Nursing Products
approval expected within the year.
Development Status
70%
Our GI portfolio is built on three synergistic pillars:
(1) natural-origin therapeutics with favorable safety profiles that address unmet needs in first-line treatment;
(2) medical devices enabling targeted, minimally invasive interventions;
(3) post-treatment care products that support the full continuum of patient management. Together, these pillars create a differentiated, end-to-end platform in gastroenterology that is difficult to replicate.
Central Nervous System (CNS)
Insomnia medication- BIC drug
Launched in Japan
License into China
Orexin receptor-based sleep-wake regulation, co-developed with a Japanese partner, addressing addiction and next-day hangover risks associated with current hypnotics.
New Mechanism Asset
NDA
License into China
A triple reuptake inhibitor for ADHD, non-controlled and non-doping, addressing abuse risk, dose-response variability, and the emotional dimension gap of current therapies.
Essential Tremor (ET) – T-type calcium antagonists
PCC
A new selective T-type calcium channel blocker targeting the core tremor-generating neural circuit, with mechanism validated by FDA Breakthrough Therapy Designation (BTD).
Ready to Transform Patient
Outcomes?
Partner with us to bring innovative therapies to patients suffering from high-prevalence, refractory conditions worldwide.